[1]刘 毅a,张 旋b,李虎宜a,等.吡格列酮对膀胱癌患者机体炎症因子抑制作用的分析[J].现代检验医学杂志,2015,30(02):46-48.[doi:10.3969/j.issn.1671-7414.2015.02.014]
　LIU Yia,ZHANG Xuanb,LI Hu-yia,et al.Inhibitory Effect Analysis of Pioglitazone on Inflammation Factors in Patients with Bladder Cancer[J].Journal of Modern Laboratory Medicine,2015,30(02):46-48.[doi:10.3969/j.issn.1671-7414.2015.02.014]
点击复制

吡格列酮对膀胱癌患者机体炎症因子抑制作用的分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年02期
页码:
46-48
栏目:
论著
出版日期:
2015-03-20

文章信息/Info

Title:
Inhibitory Effect Analysis of Pioglitazone on Inflammation Factors in Patients with Bladder Cancer
作者:
刘 毅1a; 张 旋1b; 李虎宜1a; 张栩亮1a; 权伟合1a; 吴振启2
1.湖北医药学院附属东风总医院 a.泌尿外科; b.妇产科,湖北十堰442008; 2.湖北医药学院,湖北十堰 442000
Author(s):
LIU Yi1a; ZHANG Xuan1b; LI Hu-yi1a; ZHANG Xu-liang1a; QUAN Wei-he1a; WU Zhen-qi2
1a.Department of Urologicals; 1b.Gynecology and Obstertrics, Affiliated Dongfeng General Hospital of Hubei Medical Colloge,Hubei Shiyan 442008,China; 2.Hubei Institute of Medicine,Hubei Shiyan 442000,China
关键词:
吡格列酮;  膀胱癌;  炎症因子
分类号:
R737.14; R730.53
DOI:
10.3969/j.issn.1671-7414.2015.02.014
文献标志码:
A
摘要:
目的 研究吡格列酮对膀胱癌患者机体炎症因子的抑制作用。方法 连续选择2012年2月～2014年2月来湖北医药学院附属东风总医院并诊断为膀胱癌的患者共100例,随机将其分为试验组和对照组各50例,所有患者根据病理分型和分期选择手术、化疗等方案,试验组患者同时接受吡格列酮治疗,15 mg/d×12周; 对照组接受常规的治疗方案。对比分析两组患者治疗前后的炎症因子的表达水平,高敏C反应蛋白(hs-CRP),肿瘤坏死因子α(TNF-α),白介素(IL-6)以及HOMA-IR水平,MCP-1和MIP-1因子的水平的差异性。结果 治疗后两组患者的hs-CRP,TNF-α和IL-6水平均降低,差异均有统计学意义(P<0.05),且试验组降低的更明显,差异均有统计学意义(P<0.05)。两组患者的HOMA-IR,MCP-1和MIP-1水平均降低,差异均有统计学意义(P<0.05),且试验组降低的更明显,差异均有统计学意义(P<0.05)。两组患者不良反应率的比较,差异无统计学意义(P>0.05)。结论 吡格列酮可能通过降低膀胱癌患者的炎症因子如hs-CRP,TNF-α,IL-6,HOMA-IR,MCP-1和MIP-1水平提高临床效果,改善预后。
Abstract:
Objecitve To study the inhibitory effect of pioglitazone on inflammation factors in patients with bladder cancer.Methods A total of 100 consecutives diagnosed as bladder cancer from Februray 2013 to Februray 2014 were individed randomly into experiment and control groups and each of 50 cases.All patients received the appropriate operation or chemotherapeutic regimens,and the patients in experiment group received pioglitazone(15 mg/d×12 weeks)at the same time.Then to compare expression differences of high-sensitive C reactive protein(hs-CRP),tumor necrosis factor alpha(TNF- alpha),interleukin(IL-6)and HOMA-IR,MCP-1,MIP-1 levels.Results The levels of hs-CRP,TNF-α and IL-6 in the two groups after treatment were all lower(P<0.05),and in experiment groups they were significantly lower than control group(P<0.05).The levels of HOMA-IR,MCP-1 and MIP-1 in the two groups after treatment were all lower(P<0.05),and in experiment groups they were significantly lower than control group(P<0.05).The complication rate in the two groups were no statistical difference(P>0.05).Conclusion Pioglitazone could improve clinical effect and prognosis by lowing inflammation factors including hs-CRP,TNF-α,IL-6,HOMA-IR,MCP-1 and MIP-1 in patients with bladder cancer.

参考文献/References:

[1] 申 琳,王 浩,叶 平.吡格列酮对大鼠缺血/再灌注心肌过氧化物酶体增殖物受体γ辅激活因子1α表达的影响[J].南方医科大学学报,2014,34(2):197-200. Shen L,Wang H,Ye P.Effects of pioglitazone on myocardial poroxisome proliferator-activated receptor gamma co-activator 1α expression in rats with myocardial ischemia/reperfusion injury[J].Journal Souther Medical University,2014,34(2):197-200.
[2] 李国迎.吡格列酮对大鼠脑出血后细胞凋亡因子表达的影响[D].青岛大学,2014.
[3] 汤 尧,王 健.膀胱癌相关因子研究进展[J].中国现代医生,2011,49(9):12-14. Tang Y,Wang J.Research progress of bladder cancer associated factors[J].China Modern Doctor,2011,49(9):12-14.
[4] 汪 姗,叶山东,孙文佳,等.吡格列酮对大鼠肾小球系膜细胞氧化应激的影响[J]. 中国糖尿病杂志,2014,22(1):76-78. Wang S,Ye SD,Sun WJ,at al.Effects of pioglitazone on high glucose-mediated oxidative stress in cultured mesangial cells of rats[J].China Journal of Diabetes,2014,22(1):76-78.
[5] 潘慧娟,杨新华,孙 艳,等.吡格列酮对慢性肾脏病患者血管内皮功能和肾功能的影响[J].中华全科医学,2014,12(1):72-73,89. Pan HJ,Yang XH,Sun Y,et al.Effects of pioglitazone on endothelial vasodilator function and the kidney function in patients with chronic kidney disease[J].Chinese Journal of General Practice,2014,12(1):72-73,89.
[6] 杨 红,石建丽.维格列汀与吡格列酮对2型糖尿病患者血糖控制及炎症因子的影响研究[J].中国现代药物应用,2014,8(20):82-83.
[7] Lee WY,Park JS,Noh SY,et al.C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP Ⅲ report[J].Int J Cardiol,2013,97(1):101-106.
[8] 伍仕敏,艾洪武,熊 焰,等.吡格列酮对HepG2细胞增殖和凋亡的影响及机制研究[J].中国药理学通报,2011,27(7):975-981. Wu SM,Ai HW,Xiong Y,et al.Pioglitazone inhibits cell proliferation and induces apoptosis in human HepG2 cells and the potential mechanisms[J].Chinese Pharmacological Bulletin,2011,27(7):975-981.
[9] 万政强,陈 晨,伏林山,等.吡格列酮对胶质瘤细胞生长的抑制研究[J].东南大学学报(医学版),2013,32(1):42-45. Wan ZQ,Chen C,Fu LS,et al.Peroxisome proliferator-activated receptor agonist pioglitazone inhibits glioma cell growth mediated by β-catenin[J].J Southeast Univ(Med Sci Edi),2013,32(1):42-45.

备注/Memo

备注/Memo:
基金项目:湖北省卫生厅科研基金:RAN干扰抑制DNMT基因对人体膀胱癌细胞增殖和凋亡的影响,编号:JX3B27。 作者简介:刘 毅(1981-),男,硕士研究生,主治医师,研究方向:泌尿外科,Tel:13477301258,0719-8272526,E-mail:liuy7683@163.com。 通讯作者:张 旋(1983-),女,本科,主治医师,研究方向:妇产科,E-mail:zhangx7683@163.com。
更新日期/Last Update: 2015-03-20